Comprehensive Liver Care of New Jersey
Clinical trials are key to finding better treatment for patients. To find out more on available clinical trials call Ismael Castaneda, Research Coordinator at 973-972-6812 or Heleine Kopenski at 973-972-5302
Efficacy and Safety Study of PEG-Interferon (IFN) Lambda (PEG-rIL-29) Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)
http://clinicaltrials.gov/ct2/show/NCT01001754
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
http://clinicaltrials.gov/ct2/show/NCT00829413
Autologous prime-boost anti-tumor vaccination in patients with hepatoma or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver
http://clinicaltrials.gov/ct2/show/NCT00553683
Sorafenib pre-treatment in patients undergoing Hepatic Arterial Chemo-Embolization (HACE) for unresectable hepatoma to increase tumor kill.
http://clinicaltrials.gov/ct2/show/NCT00949182
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib
http://clinicaltrials.gov/ct2/show/NCT01140347
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
http://clinicaltrials.gov/ct2/show/NCT01004978
Efficacy and Safety Study of PEG-Interferon (IFN) Lambda (PEG-rIL-29) Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)
http://clinicaltrials.gov/ct2/show/NCT01001754
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
http://clinicaltrials.gov/ct2/show/NCT00829413
Autologous prime-boost anti-tumor vaccination in patients with hepatoma or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver
http://clinicaltrials.gov/ct2/show/NCT00553683
Sorafenib pre-treatment in patients undergoing Hepatic Arterial Chemo-Embolization (HACE) for unresectable hepatoma to increase tumor kill.
http://clinicaltrials.gov/ct2/show/NCT00949182
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib
http://clinicaltrials.gov/ct2/show/NCT01140347
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
http://clinicaltrials.gov/ct2/show/NCT01004978